Amgen sets lower than expected guidance for 2022; plans up to $6B buybacks in Q1
Sundry Photography/iStock Editorial via Getty Images


Amgen (NASDAQ:AMGN) continues to trade higher in the pre-market on Tuesday after the companyâs Q4 2021 earnings surpassed Street forecasts yesterday. However, its 2022 guidance issued today has fallen short of expectations.
According to Bloomberg, Amgen (AMGN) projects $25.4B â $26.5B in revenue and $17 â $18 adjusted earnings per share for 2022, compared to average analyst estimates of ~$26.9B and $17.62 currently.

At the ongoing business review meeting today, the biotech is also expected to provide its preliminary long-term guidance for 2022 â 2030.
In 2022, the company plans to buy back $6B â $7B of its shares, including up to $6B worth of stock in the first quarter alone.

Even as Amgen (AMGN) shares fell more than 5% over the past twelve months, the average analyst ratings on the company have gradually declined on Wall Street, as shown in this graph.